TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01798004
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02527213
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional treatment(s) due to lesion progression When intervention occurs, the date of the intervening event should be recorded in the source documents and the (CRF). The subject should continue in the study as scheduled.
Study: NCT03431558
Drug: Glucon-D 99.4% (Placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will be given 100mg Glucon-D (99.4% glucose) placebo which will be similar in shape, color to the bLF.
Study: NCT03864432
Drug: Gemiglptin 50mg multiple dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemigliptin 50mg 1T \* 10days
Study: NCT00311610
Drug: SN-38 liposome
Normalized name: sn-3-GPC
DrugBank: Choline alfoscerate (DB04660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 38 mg/sq m IV infusion over 30 min q 21 days (1 cycle) until progression
Study: NCT03187197
Drug: Pradaxa®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran etexilate
Study: NCT02840162
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selective inhibition of COX-2 without significant cyclooxygenase-1 (COX-1) inhibition
Study: NCT02840162
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02325180
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02229084
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) (AC) will be administered concurrently every three weeks for four cycles followed by docetaxel (75 mg/m2) every three weeks for four cycles.
Study: NCT02229084
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) (AC) will be administered concurrently every three weeks for four cycles followed by docetaxel (75 mg/m2) every three weeks for four cycles.
Study: NCT01087502
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo mach to 5 mg linagliptin first 12 weeks of treatment once daily
Study: NCT01087502
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo maching Glimepiride 1-4 mg after 12 weeks of treatment
Study: NCT03019822
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing mannitol looking identical to the other drugs
Study: NCT02192931
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02498860
Drug: Pemebit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles
Study: NCT01370460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mL 0.9% sterile saline
Study: NCT01602055
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose 500 mg of film coated tablet
Study: NCT03166527
Drug: Immune Globulin 10% Intravenous Solution
Normalized name: Immune Globulin 10% Intravenous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard Immune lobulin 10% intravenous solution infusion at standard and high infusion rates.
Study: NCT00241982
Drug: long-circulating liposomal prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01080352
Drug: Ascorbic Acid (Vitamin C)
Normalized name: Ascorbic acid (vitamin C), plain
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60grams of ascorbate given intravenous infusion in 1000ml sterile water.
Study: NCT01292057
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match active drug Aripiprazole for 8 days
Study: NCT04003688
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution (instead of magnesium sulfate, as in the other groups)
Study: NCT00838162
Drug: TMC310911 75 mg twice daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TMC310911 75 mg twice daily orally (by mouth) on Days 1 to 14.
Study: NCT00838162
Drug: TMC310911 150 mg twice daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TMC310911 150 mg twice daily orally (by mouth) on Days 1 to 14
Study: NCT00838162
Drug: TMC310911 300 mg twice daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TMC310911 300 mg twice daily orally (by mouth) on Days 1 to 14
Study: NCT00838162
Drug: TMC310911 300 mg once daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC310911 300 mg once daily orally (by mouth) on Days 1 to 14
Study: NCT01439438
Drug: Topamax® coated tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation
Study: NCT01071876
Drug: BF2.649
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule in the morning before breakfast
Study: NCT01071876
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule in the morning before breakfast
Study: NCT00220844
Drug: Desipramine
Normalized name: Desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01529164
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200mg/m2 iv d1 ,repeat every 14 days
Study: NCT01993940
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet taken orally once a day
Study: NCT01670097
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 Blinded Phase: Two capsules by mouth twice a day for 4 days, followed by one capsule twice a day for 3 days.
Study: NCT02786446
Drug: Naproxen Sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tab Naproxen sadium 550 mg per oral will be given to patients 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
Study: NCT03677960
Drug: Topical ABI-1968 cream
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of Topical ABI-1968 Cream administered by the Investigator in the clinic up to Day 29
Study: NCT02786446
Drug: Lidocaine gel and Naproxen Sodium
Normalized name: naproxen and diphenhydramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tab Naproxen sodium 550 mg per oral will be given to patients 45 minutes before ESWL and 2% lidocain gel will be applied to coresponding lumber area 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
Study: NCT02292979
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg/m2
Study: NCT00543556
Drug: MK0767
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01500837
Drug: association of RIFAMPIN + CLINDAMYCIN
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: association of RIFAMPIN + CLINDAMYCIN
Study: NCT01500837
Drug: association of LEVOFLOXACIN+ CLINDAMYCIN
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: association of LEVOFLOXACIN+ CLINDAMYCIN
Study: NCT01228552
Drug: Topical, intra-oral ketoprofen gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.
Study: NCT02484716
Drug: Placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (NaCl) is administered by the patient with a posology of one spray (50 µL) in each nostril twice a day for 4 weeks.
Study: NCT01937767
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01211262
Drug: IMCgp100
Approvals — FDA: no, EMA: no, PMDA: no
Description: For each arm, the study will be divided into two parts: In part 1, dose escalation, the MTD or RP2D for each dosing regimen will be established. In part 2, dose expansion, a cohort of participants will be treated at the RP2D or MTD.
Study: NCT03619330
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the testosterone group Androtop gel 5 grams (50 mg of testosterone) was applied once a day on a dry skin.
Study: NCT01779362
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching to metformin 1000 mg BI
Study: NCT01209026
Drug: Placebo Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo Novel dry powder inhaler. Lactose monohydrate and magnesium stearate.
Study: NCT01476904
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mcg/inhalation, 2 inhalations QID
Study: NCT01476904
Drug: Epinephrine inhalation
Normalized name: EPINEPHrine Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mcg/inhalation, 2 inhalations QID
Study: NCT04047940
Drug: LY900020
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02345850
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mesna will be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide or administered per institutional standards. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of Mesna is equal to 80% of the total daily dose of cyclophosphamide.~Cyclophosphamide 50 mg/kg will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume).
Study: NCT02336308
Drug: Placebo, Normal Saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000623
Drug: Arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02070523
Drug: VDCLD regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02345850
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be administered at the doses of 15 mg/m\^2 IV bolus on Day +1, and 10 mg/m\^2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate should be given at least 24 hours after the hematopoietic stem cell infusion. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices. Leucovorin rescue is allowed according to institutional practices.
Study: NCT02121717
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take orally
Study: NCT02129725
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules, 1 capsule po three times a day for 3 months
Study: NCT02534870
Drug: ABT-450/r/ABT-267
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT02534870
Drug: ABT-333
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT01411774
Drug: Pill placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: The pill placebo will be identical to the active study medication in every respect (e.g., size, shape, number of capsules, etc.).
Study: NCT05055687
Drug: FL058
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2500mg、3000mg
Study: NCT05055687
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: empty bottle
Study: NCT05055687
Drug: FL058
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500mg、1000mg、2000mg
Study: NCT02670551
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01962298
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00575601
Drug: SIMVASTATIN
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/day,po,for two months until the day of hCG injection placebo pills as like as simvastatin will be used
Study: NCT03718039
Drug: HTX-011
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX-011 (bupivacaine/meloxicam), up to but not to exceed 60 mg/1.8 mg, via instillation.
Study: NCT00538863
Drug: Fentanyl sublingual spray
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl sublingual spray in doses of 100, 200, 400, 600, 800, 1200, and 1600 µg
Study: NCT01037231
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01598896
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo capsule by mouth twice daily
Study: NCT02741024
Drug: Artemether-Lumefantrine (AL)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment on site with Artemether-lumefantrine combination according to the manufacturer's dose and instruction and follow-up for a period of 42 days.
Study: NCT00851500
Drug: K-604
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-604 is given for 26 weeks
Study: NCT01806272
Drug: Compound Vitamin B12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily
Study: NCT00016653
Drug: Creatine Monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03099720
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo fluid will be given at the site of operation locally
Study: NCT04588324
Drug: SHR2150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive escalating doses of SHR-2150 (starting dose 2 mg) in 3-week treatment cycles.
Study: NCT04588324
Drug: Anti-Cancer Agent
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: The previously resistant first-line cytotoxic regimens, anti-PD-1 antibody and/or anti-CD47 antibody will be administered intravenously Q3W.
Study: NCT04588324
Drug: SHR2150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive SHR-2150 at RP2D in 3-week treatment cycles.
Study: NCT02030535
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04443725
Drug: Standard of care treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days (dose reductions for weight \< 45 kg or GFR (glomerular filtration rate) \<50ml/min) alone; as provided by the MOHP protocol),
Study: NCT04647955
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were treated for 8 weeks.
Study: NCT03280251
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks
Study: NCT00107263
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00983021
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, simultaneous dose of placebo, injected s.c. (under the skin)
Study: NCT01014117
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
Study: NCT01014117
Drug: SRT2104
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg of SRT2104.
Study: NCT01120665
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactose powder, corn starch, microcrystalline cellulose, and magnesium stearate
Study: NCT00565331
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline solution
Study: NCT01029795
Drug: LY2599506
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally (po), twice daily (BID) prior to morning and evening meals for 12 weeks
Study: NCT01976806
Drug: Placebo (for Docosahexaenoic acid)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (corn/soybean oil) capsules manufactured to look identical to DHA capsules
Study: NCT03370510
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray.
Study: NCT01029795
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules administered po, BID prior to morning and evening meals for 12 weeks
Study: NCT03916328
Drug: B/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: A third of the women will be randomized to Bictergravir /Emtricitabine / Tenofovir alafenamide (B/F/TAF; Biktarvy®).
Study: NCT03916328
Drug: TDF/3TC/EFV or DTG or NVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: A third of the women will remain on Tenofovir Disoproxil Fumurate.(TDF) containing ART.
Study: NCT00613249
Drug: HEC-based Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravaginal gel, dosed daily
Study: NCT02177305
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03578822
Drug: rhPro-UK simulation agent
Normalized name: Vital E- Repro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive rhPro-UK simulation agent 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.
Study: NCT04483596
Drug: melatonin effect on the Abbreviated Mental Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Questionnare~1. Age~2. Time (to nearest hour)~3. Address for recall at end of test (Ask patient to repeat the address to ensure it has been heard correctly)~4. Year~5. Name of hospital~6. Recognition of two persons (e.g. doctor, nurse)~7. Date of birth~8. Year of any famous event e.g: the last Egyptian revolution~9. Name of the present monarch~10. Count backwards from 20 to 1
Study: NCT03573336
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intake orally, once daily
Study: NCT03070782
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile normal saline (0.9% NaCl)
Study: NCT04148287
Drug: APX001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1: APX001 1000 mg IV BID over a 3-hour infusion Days 2-3: APX001 600 mg IV QD over a 3-hour infusion Days 4 - 42: APX001 600 mg IV QD over a 3-hour infusion or APX001 800 mg QD oral.
Study: NCT01525628
Drug: caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CYP1A2 probe drug
Study: NCT00239005
Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01750827
Drug: SB659032
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT03045198
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03097692
Drug: Pharmacologic preconditionig
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic preconditionig will be attained by sevoflurane anesthesia
Study: NCT00080795
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00530166
Drug: sham comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3(100 mg) tablets once daily for 12 weeks
Study: NCT01709903
Drug: QVA149
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVA149 110/50 µg capsules q.d. for inhalation, delivered via Novartis single dose dry powder inhaler (SDDPI).
Study: NCT01709903
Drug: Placebo to QVA149
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to QVA149 with SDDPI
Study: NCT04872231
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PART A (SAD): Placebo capsules will be supplied as one to eight capsules. Each capsule contains placebo inhalation powder. The capsules will be matched for use within the provided Plastiape RS00 Dry Powder inhaler device (Model 8). Doses may require multiple inhalations through the inhaler device. All inhalations must be conducted within a maximum of 10-minute period.~Subjects in PART A will receive a single dose of placebo.~PART B (MAD): Placebo will be supplied as one to eight capsules. Each capsule contains placebo inhalation powder. The capsules will be matched for use within the provided Plastiape RS00 Dry Powder inhaler device (Model 8). Doses may require multiple inhalations through the inhaler device. All inhalations must be conducted within a maximum of 10-minute period.~Subjects in PART B will receive Placebo BID for a total of 13 doses.
Study: NCT01464489
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1 Normal saline intravenous injection during anesthetic induction After 120 sec of normal saline injection, record intubating condition
Study: NCT04093596
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy for lymphodepletion
Study: NCT04092595
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg oral tablet
Study: NCT04511845
Drug: SPYK04
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPYK04 capsule
Study: NCT04731324
Drug: ZYIL1 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: NLRP3 inflammasome inhibitor